Interestingly, treatment of HER2-overexpressing breast cancer cell lines (SKBR-3 and BT-474) with the combination of lapatinib and SFN synergistically induced chemosensitization to lapatinib and decreased cell viability through the suppression of p-HER2, p-Akt, and p-S6 [74]. The gene discussed is ERBB2; the disease is breast carcinoma.